Litcius/Paper detail

Second-generation BTK inhibitors hit the treatment bullseye with fewer off-target effects

Maggie L. Shaw;

2020The American Journal of Managed Care17 citationsDOI

Abstract

BY GRADE SCHOOL, most of us have a basic understanding of DNA, or deoxyribonucleic acid, the essential building block of human life.It's what makes our eyes blue or our hair straight.DNA medicines, however, are less well known and historically have been unsuccessful in delivering what 25 years ago was touted as a revolution in therapeutics. 1Contrary to popular opinion, DNA medicines are not synonymous with "gene therapy," but they have been challenged by the same biases and presumptions, and because of that, DNA medicines have failed to gain therapeutic ground in the treatment of human disease.Until now.

Topics & Concepts

MedicineBruton's tyrosine kinaseInternal medicineIntensive care medicineTyrosine kinaseReceptorChronic Lymphocytic Leukemia ResearchCancer Mechanisms and Therapyinterferon and immune responses
Second-generation BTK inhibitors hit the treatment bullseye with fewer off-target effects | Litcius